Back to Newsroom
Back to Newsroom

SESN, GNRC & PYPL - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Deadlines

Friday, 10 September 2021 11:00 AM

Bronstein, Gewirtz and Grossman, LLC

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / September 10, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Bronstein, Gewirtz and Grossman, LLC, Friday, September 10, 2021, Press release picture

Sesen Bio, Inc. (NASDAQ:SESN)
Class Period: December 21, 2020 - August 17, 2021
Deadline: October 18, 2021
For more info: www.bgandg.com/sesn.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose: (1) that Sesen Bio's clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) that three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) that, as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Generac Holdings Inc. (NYSE:GNRC)
Class Period: February 23, 2021 - July 29, 2021
Deadline: October 19, 2021
For more info: www.bgandg.com/gnrc.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Generac's portable generators posed an unreasonable risk of injury to users and the public; (2) as a result, at least seven finger amputations and one crushed finger had been reported to the Company; (3) as a result, Generac would face increased regulatory scrutiny; (4) the Company would end sales in its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada in June 2021; (5) the Company would recall its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada; (6) the end of sales and the recall would occur before the Company's noted hurricane and wildfire seasons and following the Texas outage-periods the Company has touted for sales; and (7) as a result, defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.

PayPal Holdings, Inc. (NASDAQ:PYPL)
Class Period: February 9, 2017 - July 28, 2021
Deadline: October 19, 2021
For more info: www.bgandg.com/pypl.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PayPal had deficient disclosure controls and procedures; (2) as a result, PayPal's business practices with respect to PayPal Credit remained non-compliant with applicable laws and/or regulations; (3) PayPal's practices regarding payment of interchange rates related to its debit cards were likewise non-compliant with applicable laws and/or regulations; (4) accordingly, PayPal's revenues derived from its PayPal Credit and debit card practices were in part the subject of improper conduct and thus unsustainable; (5) all the foregoing subjected the Company to an increased risk of regulatory investigation and enforcement; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: